Guggenheim Capital LLC Apellis Pharmaceuticals, Inc. Transaction History

Guggenheim Capital LLC

$14 Billion
Q3 2024

A detailed history of Guggenheim Capital LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 37,929 shares of APLS stock, worth $1.26 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

37,929

Previous 33,613 12.84%

Holding current value

$1.26 Million

Previous $1.29 Million 15.21%

% of portfolio

0.01%

Previous 0.01%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$28.84 - $41.15 $124,473 - $177,603	4,316 Added 12.84%	37,929 $1.09 Million
Q2 2024 Aug 14, 2024	BUY	$38.07 - $59.71 $4,225 - $6,627	111 Added 0.33%	33,613 $1.29 Million
Q1 2024 May 14, 2024	BUY	$55.39 - $72.47 $107,013 - $140,012	1,932 Added 6.12%	33,502 $1.97 Million
Q4 2023 Feb 14, 2024	SELL	$37.14 - $64.82 $354,129 - $618,058	-9,535 Reduced 23.2%	31,570 $1.89 Million
Q3 2023 Nov 14, 2023	BUY	$23.65 - $89.22 $228,104 - $860,526	9,645 Added 30.66%	41,105 $1.56 Million
Q2 2023 Aug 11, 2023	SELL	$76.68 - $93.31 $347,513 - $422,880	-4,532 Reduced 12.59%	31,460 $2.87 Million
Q1 2023 May 10, 2023	SELL	$46.59 - $66.96 $597,050 - $858,092	-12,815 Reduced 26.26%	35,992 $2.37 Million
Q4 2022 Feb 14, 2023	BUY	$43.24 - $61.04 $574,573 - $811,099	13,288 Added 37.41%	48,807 $2.52 Million
Q3 2022 Nov 14, 2022	SELL	$44.76 - $69.66 $275,676 - $429,035	-6,159 Reduced 14.78%	35,519 $2.43 Million
Q2 2022 Aug 15, 2022	SELL	$35.07 - $59.21 $49,834 - $84,137	-1,421 Reduced 3.3%	41,678 $1.88 Million
Q1 2022 May 16, 2022	SELL	$35.46 - $54.12 $182,689 - $278,826	-5,152 Reduced 10.68%	43,099 $2.19 Million
Q4 2021 Feb 14, 2022	BUY	$30.74 - $49.16 $141,619 - $226,480	4,607 Added 10.56%	48,251 $2.28 Million
Q3 2021 Nov 15, 2021	BUY	$31.4 - $69.84 $1.37 Million - $3.05 Million	43,644 New	43,644 $1.44 Million

Others Institutions Holding APLS

# of Institutions

308

Shares Held

115M

Call Options Held

3.85M

Put Options Held

1.09M

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.66B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Account

Guggenheim Capital LLC Apellis Pharmaceuticals, Inc. Transaction History